Summit Therapeutics Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Material agreementSep 28 →Insiders4 insiders bought $114.6M in 9 open-market buys. No sales.→HoldersBaker Bros 4.1%FMR 1.3%State Street 1.2%→Financing →PeersClosest companies: ORIC, ERAS, TNGX→
From the filings
Figures
- Net income
- −$856.1Mlast 12 months
- Operating cash flow
- −$384.1Mlast 12 months
- Cash and equivalents
- $419.4Mat the last balance sheet
- Shares outstanding
- 793.1M shareson issue